Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics develops conditionally active antibodies designed to function selectively in the tumor microenvironment, aiming to harness the immune system against cancer. Their approach involves innovative, highly selective therapeutics that target challenging immuno-oncology targets, with a focus on improving safety and efficacy through pH-sensitive antibody design. The company is committed to advancing cancer immunotherapy by overcoming previous challenges in drug selectivity and pharmacokinetics, and their pipeline includes investigational medicines like SNS-101 targeting VISTA and other immune checkpoints.
Industries
Nr. of Employees
medium (51-250)
Sensei Biotherapeutics, Inc.
Gaithersburg, Maryland, United States, North America
Patents
Modified antibodies and related compounds, compositions and methods of use
US-11932695-B2
View DetailsLinkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US-11229711-B2
View Details
Modified antibodies and related compounds, compositions and methods of use
US-11932695-B2
View DetailsLinkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US-11229711-B2
View DetailsProducts
Platform for conditionally active antibodies activated in low‑pH tumor microenvironment
A discovery and design platform that produces antibodies engineered to preferentially bind targets under acidic conditions to localize activity to the tumor microenvironment and reduce peripheral on‑target binding.
Clinical‑stage pH‑sensitive antibody targeting a myeloid checkpoint (clinical‑stage; IND cleared)
A pH‑selective monoclonal antibody designed to bind an active form of a myeloid checkpoint within the acidic tumor microenvironment; advanced into Phase 1/2 clinical testing following IND clearance.
Discovery‑stage conditionally active antibodies against additional immunoregulatory targets
Discovery programs applying the low‑pH conditional activation approach to other immunoregulatory targets (discovery stage for multiple myeloid or immunosuppressive pathway targets).
Platform for conditionally active antibodies activated in low‑pH tumor microenvironment
A discovery and design platform that produces antibodies engineered to preferentially bind targets under acidic conditions to localize activity to the tumor microenvironment and reduce peripheral on‑target binding.
Clinical‑stage pH‑sensitive antibody targeting a myeloid checkpoint (clinical‑stage; IND cleared)
A pH‑selective monoclonal antibody designed to bind an active form of a myeloid checkpoint within the acidic tumor microenvironment; advanced into Phase 1/2 clinical testing following IND clearance.
Discovery‑stage conditionally active antibodies against additional immunoregulatory targets
Discovery programs applying the low‑pH conditional activation approach to other immunoregulatory targets (discovery stage for multiple myeloid or immunosuppressive pathway targets).
Expertise Areas
- Tumor microenvironment–targeted immunotherapy
- Antibody engineering and conditionally active biologics
- Bispecific antibody development
- Preclinical pharmacokinetics and toxicology
Key Technologies
- pH‑sensitive conditionally active antibodies
- Bispecific antibody platforms
- Structural biology (co‑crystal/epitope mapping)
- Pharmacokinetic profiling in non‑human primates